TOKYO (dpa-AFX) - Nxera Pharma Co., Ltd. (SOLTF, 4565.T) announced it has reached a second milestone in its multi-target discovery collaboration with AbbVie focused on neurological diseases. This milestone, tied to the identification of validated and differentiated hit molecules against a neurology target, triggers a payment of US$10 million to Nxera, which will be recognized in the third quarter of 2025.
Established in 2022, the collaboration leverages Nxera's NxWave platform to discover novel therapeutics targeting G protein-coupled receptors (GPCRs) associated with neurological conditions.
Under the agreement, Nxera is eligible to receive up to US$40 million in near-term research milestone payments, in addition to potential option, development, and commercial milestones totaling up to US$1.2 billion, plus tiered royalties on global sales.
This is the second milestone reached under the collaboration, following the first milestone in June 2024.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
